A progressive stage IIIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Vladimirs Sorokins¹, Andra Tilgase², Evija Olmane³, Sergejs Isajevs⁴, Tatjana Zablocka⁴, Agnija Rasa² and Pēteris Alberts²

Abstract
Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia. A female patient was diagnosed with stage IIIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, ECHO-7 virus oncolytic virotherapy was started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not received any other treatment than surgery and oncolytic virotherapy. No severe adverse events have been reported during virotherapy. The present case suggests that ECHO-7 virotherapy is an effective treatment of skin melanoma.

Keywords
ECHO-7, melanoma, metastatic melanoma, oncolytic virus, virotherapy, Rigvir

Date received: 27 October 2019; accepted: 25 May 2020

Introduction
Research of cancer cell biology has shown that the changes that occur in the cancer cells make them more susceptible to viral infections. In order to avoid recognition by the immune system, several pathways are altered, for example, the interferon-mediated pathway. Both wild type and genetically engineered viruses have the ability to infect cancer cells while sparing the healthy cells of the organism. Currently, oncolytic viruses are tested for various indications, malignant melanoma being one of them. Oncolytic viruses not only infect cancers cells and thus destroy them, but can also induce immune system reaction. When oncolytic viruses propagate and the cancer cell undergoes apoptosis, new viral particles, tumour associated antigens (TAA), damage associated molecular patterns (DAMP) and pathogen associated molecular patterns (PAMP) are released and induce an immune system response. Therefore, it has been suggested that oncolytic viruses not only directly kill cancer cells, but also expose them to the immune system.²

ECHO-7 virus strain Rigvir is a positive sense single stranded RNA virus that has been selected and adapted for melanoma. It was registered in Latvia in 2004. A retrospective study has shown that stage IB–IIIC melanoma patients benefit from ECHO-7 therapy after a surgery. In comparison to the control group, patients who received ECHO-7 virotherapy had 4.39- to 6.57-fold lower mortality. ECHO-7 was well tolerated and no severe adverse event was observed.³

Talimogene laherparepvec is a herpes simplex type 1 virus that has been genetically modified to express human granulocyte–macrophage colony-stimulating factor (GM-CSF). Talimogene laherparepvec is approved for treatment of advanced melanoma in the United States and Europe since 2015.⁴ Clinical trials involving unresected stage IIIB to IV melanoma patients showed increased durable response rate.
objective response rate, and progression-free survival in the Talimogene laherparepvec study arm.\(^5\)

HF-10, Reovirus Serotype 3 - Dearing Strain, Vaccinia virus, Coxsackie virus A21 and adenovirus are also currently in clinical trials for melanoma treatment. Clinical studies involve not only monotherapy, but also combination therapy treatment.\(^6\)

Here we report a stage IIIB melanoma patient that has received oncolytic virotherapy with ECHO-7 virus after disease progression. The patient has been treated with ECHO-7 virus for over 70 months, experienced one more relapse in April 2015, but since then she has been stable for over 60 months. The patient has not received any other concomitant treatment post-surgery.

Results

A female patient at the age of 78 felt a small lesion in the bottom of the heel which then turned into ulcer. Surgical excision of the lesion was performed on 29 December 2010 with subsequent inguinal lymphadenectomy in February 2011.

The histopathological examination showed that the primary tumour was composed of spindle, epithelioid and nevoid cells, with large, round and elongated nuclei with prominent vesicular nuclei, large nucleoli, abundant eosinophilic cytoplasm with focal melanin pigment, focal necrosis, haemorrhage, epidermal ulceration, with moderate lymphocyte infiltration, invasion in sinus lymph vessels without vascular and perineural invasion. The tumour cells demonstrated marked nuclear pleomorphism with variation in cell size, shape and staining with increased number of mitosis up to 58/mm\(^2\) (Figure 1(a) and (b)). The tumour was Melan A immunopositive (Figure 1(c)).

In addition, the melanoma metastasis to the right inguinal lymph node was observed. The TNM staging was T3bN1bM0. Clark level 4 and Breslow 3 mm. The metastatic lymph nodes were up to 4.0 cm.

A computed tomography (CT) scan in February 2012 did not show metastases in the lungs or in the retroperitoneal area (Figure 2(a) and (b)). Fibrous infiltration in the subcutaneous adipose tissue in the right inguinal area was observed in February 2012 (Figure 2(c)) and in May 2012 (Figure 2(d)).

In 2013, cutaneous metastases in the sole of the foot, right leg medial, lateral and posterior surface, as well as at the right inguinal part were observed. During the surgery on 28 May 2013, 9 subcutaneous and dermal lesions with diameter of 0.3–1.0 cm were excised. The tumour did not exhibit any degree of regression (Figure 1(d)).

On 7 August 2014, ECHO-7 virotherapy was started (2 ml intramuscular injections, \(10^6\) TCID\(_{50}\)/ml alternately in left and right gluteus and deltoid muscles); the first 4 months ECHO-7 virus administration was every 3 weeks. Subsequent administrations have so far been with an average interval of 30.8 days. The patient has received a total of
62 administrations by 12 September 2019 and ECHO-7 virotherapy is ongoing.

In April 2015 a CT scan showed metastases in 5 right paralilacal and 6 paraaortal lymph nodes with capsular invasion. The CT also showed lesions 0.4 cm in diameter were observed, and (e) 22 April 2015. Lesions in left lung basal part 0.4 cm in diameter were observed, (g–i) 22 April 2015. Enlarged lymph nodes retroperitoneal perical right area 3.0 cm x 2.5 cm and paraalilacal right area 3.8 cm x 4.7 cm, (j and k) 19 February 2018. Lesions in basal part of both lungs 0.4–0.5 cm, (l–o) 19 February 2018. Enlarged lymph nodes in retroperitoneal interaortacaval area 1.4–1.8 cm, enlarged lymph node in right paralilacal side up to 2.1 cm x 4.6 cm, enlarged lymph nodes in inguinal area, in the right side up to 1.4 cm in diameter, and up to 1.3 cm in diameter in the left side were observed.

The patient has not received any other treatment besides surgery and ECHO-7 virotherapy. No adverse events have been observed during the therapy with ECHO-7 virus strain.

**Discussion**

The foot is considered a problematic spot for melanoma. The disease may be confusing, leading to misdiagnosis of the lesion. As with any type of malignant melanoma, the most important survival indicators are tumour thickness, ulceration and lymph node metastases. Because of infrequent checks of the acral skin, the lesion is often diagnosed quite late with big tumour thickness. Furthermore, there is increased risk for thick melanomas to reappear on the acral skin of the upper part of the leg.

Oncolytic virotherapy for melanoma is increasingly emerging as a novel treatment that can both have a direct effect on the tumour and also induce a systemic immune response. Studies of oncolytic viruses for various cancers are ongoing; both as combination treatments and monotherapies. The first oncolytic virus registered by the FDA and EMA is talimogene laherparepvec, which is used in advanced melanoma and has shown efficacy on overall survival for patients with cutaneous metastases. Available data show that the expected survival for stage IIIB melanoma patients...
treated according to standard treatments in the United States 9.4 years after diagnosis is approximately 45%.12

Conclusion
The present patient was diagnosed over 9.4 years ago. After several recurrences and progression episodes, stabilization of the disease has been observed since June 2015, for over 70 months during virotherapy treatment. The present case suggests that ECHO-7 virotherapy is an effective treatment for cutaneous melanoma.

Authorship
All authors attest that they meet the current ICMJE criteria for Authorship.

Declaration of conflicting interest
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.T., A.R., and P.A. are employees of the Rigvir group. V.S., E.O., and S.I. state no conflict of interest.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed consent
Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iDs
Andra Tilgase https://orcid.org/0000-0002-3385-5182
Agnija Rasa https://orcid.org/0000-0001-6561-9371
Pēteris Alberts https://orcid.org/0000-0001-9585-9288

References
1. Russell SJ, Peng KW and Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30(7): 658–670.
2. Bayan C-AY, Lopez AT, Gartrell RD, Komatsubara KM, et al. The role of oncolytic viruses in the treatment of melanoma. Curr Oncol Rep 2018; 20(10): 80.
3. Doniņa S, Strēle I, Proboka G, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res 2015; 25(5): 421–426.
4. Bommarreddy PK, Patel A, Hossain S, et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol 2017; 18(1): 1–15.
5. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33(25): 2780–2788.
6. Lemos de, Matos A, Franco LS and McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev 2020; 17: 349–358.
7. Gray RJ, Pockaj BA, Vega ML, et al. Diagnosis and treatment of malignant melanoma of the foot. Foot Ankle Int 2006; 27(9): 696–705.
8. Bristow IR, de Berker DA, Acland KM, et al. Clinical guidelines for the recognition of melanoma of the foot and nail unit. J Foot Ankle Res 2010; 3: 25.
9. Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017; 170(6): 1109–1119.
10. Russell SJ and Peng K-W. Oncolytic virotherapy: a contest between apples and oranges. Mol Ther 2017; 25(5): 1107–1116.
11. Haitz K, Khorasvi H, Lin JY, et al. Review of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol 2020; S0190-9622: 30123–30127.
12. Edge SB, Byrd DR, Compton CC, et al. American joint committee on cancer (AJCC) cancer staging manual. 7th ed. New York: Springer, 2010, pp. 1–648.